Insulin highly respirable microparticles

Details Insulin highly respirable microparticles Insulin highly respirable microparticles

2004-03-26

2009-12-01

Kosar, Andrew D (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S303000, C424S001330

Reexamination Certificate

active

07625865

ABSTRACT:
The invention describes novel dried powders of peptide therapeutic agent useful for producing highly respirable aerosols and the methods for their manufacture. Insulin is the peptide therapeutic agent in the preferred embodiment. The powders of insulin prepared for pulmonary administration are characterized by the peculiar structure and shape of the microparticles that allow the powder to flow and to be easy aerosolized. Typical dry powder of insulin described in this patent show corrugated, nonagglomerated microparticles with a low tapped density. The mean geometric diameter (particle size) ranges between 1.0 and 10.0 micron and the mass median aerodynamic diameter (MMAD) ranges between 1.0 and 4.0 micron. These insulin pulmonary powders exhibit in vitro a very high respirable fraction (>75%).

REFERENCES:
patent: 3921637 (1975-11-01), Annette et al.
patent: 4338931 (1982-07-01), Cavazza
patent: 5320094 (1994-06-01), Laube et al.
patent: 6306440 (2001-10-01), Baeckstroem et al.
patent: 6582728 (2003-06-01), Platz et al.
patent: 2002/0052310 (2002-05-01), Edwards et al.
patent: 2003/0165436 (2003-09-01), Staniforth et al.
patent: 0467172 (1992-01-01), None
patent: 0505966 (1992-09-01), None
patent: 0520748 (1992-12-01), None
patent: 0655237 (1995-05-01), None
patent: WO 88/04556 (1988-06-01), None
patent: WO 90/07351 (1990-07-01), None
patent: WO 90/09780 (1990-09-01), None
patent: WO 91/02545 (1991-03-01), None
patent: WO 93/02712 (1993-02-01), None
patent: WO 95/24183 (1995-09-01), None
patent: WO 99/55362 (1999-11-01), None
patent: WO 99/66903 (1999-12-01), None
patent: WO 00/00176 (2000-01-01), None
patent: WO 01/93837 (2001-12-01), None
patent: WO 02/053190 (2002-07-01), None
Stahl, et al., 2002, International Journal of Pharmaceutics, 233, 227-237.
International Search Report.
Büchi, Labortechnik AG, Flawil, Switzerland (Spec.).
Forbes et al., “Water Vapor Sorption Studies . . . ”, Journal of Pharmaceutical Sciences, 1998, vol. 87, No. 11, pp. 1316-1321. (ISR).
Todo et al., “Effect of additives on insulin absorption from . . . ”, International Journal of Pharmaceutics, 2001, vol. 220, No. 1-2, pp. 101-110. (ISR).
Quaglia F et al., “Feeding liquid, non-ionic surfactant . . . ”, Journal of Controlled Release, 2003, vol. 86, No. 2-3, pp. 267-278. (ISR).
A.L. Jones, “Proceedings of the third European . . . ”, 1987, vol. 2, pp. 143-149. (Spec).
Colthorpe et al., Pharmaceutical Research, 1992, vol. 9, pp. 764-768. (Spec).
Komoda, F., J. Phar. Sci., 1994, vol. 83, pp. 863-867. (Spec).
Diabetes Care, 1990, vol. 13, pp. 953-954. (Spec).
Lee, S., J. Phar. Sci., 1976, vol. 65, pp. 567-572. (Spec).
Patton, J.S., “Inhaled Insulin”, Adv. Drug Del. Rev. 35, 1999, pp. 235-247. (Spec).
Langer, R. et al., J. App. Physiol., 1998, vol. 85, pp. 379-385. (Spec).
Nagai, T., J. Contr. Rel., 1984, vol. 1, pp. 15-22. (Spec).
Rydén, L., Int. J. Pharm. 1982, vol. 83, pp. 1-10. (Spec).
European Pharamcopeia, 4thEdition, <2.9.18> p. 216. (Spec), Jan. 2002.
A.L. Jones et al., “An Investigation of the Pulmonary Absorption of Insulin in the Rat. ” “Proceedings of the third European . . . ” 1987, vol. 2, pp. 143-149. (Spec).
Colthorpe et al., “The Pharmacokinetics of Pulmonary-Delivered Insulin: A Comparison of Intratracheal and Aerosol Administration to the Rabbit.” Pharmaceutical Research, 1992, vol. 9, pp. 764-768. (Spec).
Komoda, F. et al., “Intratracheal Delivery of Peptide and Protein Agents: Absorption from Solution and Dry Powder by Rat Lung.” J. Phar. Sci., 1994, vol. 83, pp. 863-867. (Spec).
“Monomeric Insulins and Their Experimental and Clinical Implications.” Diabetes Care, 1990, vol. 13, pp. 953-954. (Spec).
Lee, S. et al., “Development of an Aerosol Dosage Form Containing Insulin.” J. Phar. Sci., 1976, vol. 65, pp. 567-572. (Spec).
Patton, J.S. “Inhaled Insulin”, Advanced Drug Delivery Reviews 35, 1999, pp. 235-247. (Spec).
Edwards, D.A. et al., “Recent advances in pulmonary drug delivery using large, porous inhaled particles.” J. App. Physiol., 1998, vol. 85, pp. 379-385. (Spec).
Nagai, T. et al., “Powder dosage form of insulin for nasal administration.” J. Contr. Rel., 1984, vol. 1, pp. 15-22. (Spec).
Rydén, L. et al., “Effect of polymers and microspheres on the nasal absorption of insulin in rats.” Int. J. Pharm. 1992, vol. 83, pp. 1-10. (Spec).
European Pharamcopeia, 4thEdition, “Preparations for inhalations: Procedure for powder inhalers.” <2.9.18> p. 216-217. (Spec), 2002 .
European Pharamcopeia, 4thEdition, “Insulin, Bovine; Insulin, Human . . . ” pp. 1368-1381, 2002.

Affiliated with

Also associated with

Rating

Insulin highly respirable microparticles does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Insulin highly respirable microparticles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Insulin highly respirable microparticles will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4147518